Overview

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.

Phase:

Phase 2

Details

Lead Sponsor:

Xeris Pharmaceuticals

Collaborators:

Emissary International LLC
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Treatments:

Glucagon
Glucagon-Like Peptide 1